Adis Summary of Research: Safety, Effectiveness, and Immunogenicity 6 Months After BNT162B2 mRNA Vaccine in Frail Nursing Home Residents

被引：0
|
作者：
Paik, Julia [1 ]
Al-Salama, Zaina T. [1 ]
机构：
[1] Springer Nat, Private Bag 65901, Auckland 0754, New Zealand
来源：
DRUGS & THERAPY PERSPECTIVES | 2023年 / 39卷 / 09期
关键词：
D O I：
10.1007/s40267-023-01010-3
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Coronavirus disease 2019 (COVID-19) has a high mortality rate among the elderly, particularly among frailer and older individuals living in long-term care facilities (LTCFs). In Spain, a large number of patients in this priority group had received the COVID-19 vaccine, including the mRNA vaccine BNT162B2, by April 2021. This Adis Summary of Research summarizes the effects of the BNT162B2 mRNA vaccine among residents in an LTCF in Spain, based on an observational study. Vaccination in elderly LTCF residents was not linked with an increased safety risk, with no apparent contraindications even in more frail individuals.
引用
收藏
页码：317 / 318
页数：2
相关论文
共 50 条
  • [1] Adis Summary of Research: Safety, Effectiveness, and Immunogenicity 6 Months After BNT162B2 mRNA Vaccine in Frail Nursing Home Residents
    Julia Paik
    Zaina T. Al-Salama
    Drugs & Therapy Perspectives, 2023, 39 : 317 - 318
  • [2] Safety, Effectiveness, and Immunogenicity 6 Months After BNT162B2 mRNA Vaccine in Frail Nursing Home Residents
    Pablo Montejano-Hervás
    Javier Gómez-Pavón
    Olga Tornero-Torres
    Mª Victoria Valverde-Moyar
    Beatriz Martín Cruz
    Maribel Vela Carbonera
    Raquel Fuentes-Irigoyen
    Pilar Tejada González
    Margarita González-Becerra
    Esther Higueras Sánchez
    Primitivo Ramos Cordero
    Drugs & Aging, 2022, 39 : 587 - 595
  • [3] Safety, Effectiveness, and Immunogenicity 6 Months After BNT162B2 mRNA Vaccine in Frail Nursing Home Residents
    Montejano-Hervas, Pablo
    Gomez-Pavon, Javier
    Tornero-Torres, Olga
    Valverde-Moyar, Ma Victoria
    Martin Cruz, Beatriz
    Vela Carbonera, Maribel
    Fuentes-Irigoyen, Raquel
    Tejada Gonzalez, Pilar
    Gonzalez-Becerra, Margarita
    Higueras Sanchez, Esther
    Ramos Cordero, Primitivo
    DRUGS & AGING, 2022, 39 (07) : 587 - 595
  • [4] Immunogenicity after 6 months of BNT162b2 vaccination in frail or disabled nursing home residents: The COVID-A Study
    Salmeron Rios, Sergio
    Mas Romero, Marta
    Cortes Zamora, Elisa Belen
    Tabernero Sahuquillo, Maria Teresa
    Romero Rizos, Luis
    Manuel Sanchez-Jurado, Pedro
    Sanchez-Nievas, Gines
    Blas Senalada, Jose Joaquin
    Garcia Nogueras, Inmaculada
    Estrella Cazalla, Juan de Dios
    Andres-Pretel, Fernando
    Romero, Antonio Murillo
    Lauschke, Volker Martin
    Stebbing, Justin
    Abizanda, Pedro
    Cespedes, Almudena Avendano
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2022, 70 (03) : 650 - 658
  • [5] Immunogenicity of the BNT162b2 vaccine in frail or disabled nursing home residents: COVID-A study
    Salmeron Rios, Sergio
    Mas Romero, Marta
    Cortes Zamora, Elisa Belen
    Tabernero Sahuquillo, Maria Teresa
    Romero Rizos, Luis
    Sanchez-Jurado, Pedro Manuel
    Sanchez-Nievas, Gines
    Senalada, Jose Joaquin Blas
    Garcia Nogueras, Inmaculada
    Estrella Cazalla, Juan de Dios
    Andres-Pretel, Fernando
    Murillo Romero, Antonio
    Lauschke, Volker Martin
    Stebbing, Justin
    Abizanda, Pedro
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2021, 69 (06) : 1441 - 1447
  • [6] Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
    Thomas, S. J.
    Moreira, E. D., Jr.
    Kitchin, N.
    Absalon, J.
    Gurtman, A.
    Lockhart, S.
    Perez, J. L.
    Marc, G. Perez
    Polack, F. P.
    Zerbini, C.
    Bailey, R.
    Swanson, K. A.
    Xu, X.
    Roychoudhury, S.
    Koury, K.
    Bouguermouh, S.
    Kalina, W., V
    Cooper, D.
    Frenck, R. W., Jr.
    Hammitt, L. L.
    Tureci, O.
    Nell, H.
    Schaefer, A.
    Unal, S.
    Yang, Q.
    Liberator, P.
    Tresnan, D. B.
    Mather, S.
    Dormitzer, P. R.
    Sahin, U.
    Gruber, W. C.
    Jansen, K. U.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (19): : 1761 - 1773
  • [7] Humoral and Cellular Immunogenicity of the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Nursing Home Residents
    Van Praet, Jens T.
    Vandecasteele, Stefaan
    De Roo, Anneleen
    De Vriese, An S.
    Reynders, Marijke
    CLINICAL INFECTIOUS DISEASES, 2021, 73 (11) : 2145 - 2147
  • [8] Reduced immunogenicity of the mRNA vaccine BNT162b2 in patients with IPF
    Karampitsakos, T.
    Dimeas, I
    Tsiri, P.
    Sotiropoulou, V
    Tomos, I
    Papanikolaou, I
    Katsaras, M.
    Kirgou, P.
    Daniil, Z.
    Gourgoulianis, K.
    Papalexatos, D.
    Sampsonas, F.
    Manali, E.
    Papiris, S.
    Bouros, D.
    Tzouvelekis, A.
    Papaioannoui, o
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [9] Effectiveness of a Third Dose of BNT162b2 mRNA Vaccine
    Saciuk, Yaki
    Kertes, Jennifer
    Stein, Naama Shamir
    Zohar, Anat Ekka
    JOURNAL OF INFECTIOUS DISEASES, 2022, 225 (01): : 30 - 33
  • [10] Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers
    Rojkovich, Bernadette
    Nemeth, Dora
    Torok, Eszter
    Szabo, Bernadette
    Pinter, Agnes
    Juhasz, Istvan
    Weidl, Marton
    Lanyi, Eva
    Pavel-Szecsko, Judit
    Lazar, Imre
    Perduk, Andras
    Reiter, Jozsef
    Nagy, Gyorgy
    Nagy, Erzsebet
    Geher, Pal
    ORVOSI HETILAP, 2021, 162 (39) : 1551 - 1557
12345